Nova Biosciences
Privately-held biotechnology company founded by Dr. Amelia T. Murphy following her resignation from UN research service (~2122). Funded entirely by Omani private capital after UN funding pathways proved too slow for the startup’s runway.
Develops a redesigned version of the TIGR-Tas nanoscale delivery platform, originally co-developed by Murphy and Dr. Mark Lee Spencer at Dome 1 (2110). The company’s platform, codenamed Project Prometheus, targets radiation-induced cellular damage and, as an unplanned secondary effect, produces measurable anti-aging outcomes — telomere elongation, DNA methylation reversal, and extended lifespan in animal models — through a non-integrating, transient telomerase-mimetic mechanism requiring annual or semi-annual re-dosing.
The platform’s commercial targets are high-value niche markets: long-duration space habitation, space hotel guests, and deep-space crews. Manufacturing costs remain too high for general population deployment as of 2124.
Nova Biosciences’ disclosure strategy withholds the Aging Core payload as trade secret alongside patent filings — a commercial parallel to Cognitive Genesis Research’s 2045 voluntary technical redaction, though motivated by competitive advantage rather than containment.